Clinical Trials Arena on MSN
CVRx’s stock up as heart failure device to be trialled in expanded patient group
The device gained approval in the US in 2019 and received CE marking for use in the EU in 2014.
A Tale of Two Citizens: A State Attorney General and a Hematologist Facilitate Translation of Research Into US Food and Drug Administration Actions—A SONAR Report The median age was 71 years, and 54% ...
Study links exosomal microRNA to ventricular remodelling in heart failure. Discover how this biomarker could inform future ...
Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...
A new meta-analysis finds no clear long-term cardiovascular benefit from beta-blockers after myocardial infarction in ...
The Heart Failure Society of America (HFSA), the Heart Failure Association of the European Society of Cardiology (HFA of the ESC), and the Japanese Heart Failure Society (JHFS) announced today a new ...
Adults who have heart failure with a left ventricular ejection fraction of 40% or more face a high risk of hospitalization for heart failure and cardiovascular death. People who have heart failure ...
Patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF) commonly have improvements in their LVEF, but that doesn’t mean they can let their guard down, data from a large ...
Verywell Health on MSN
Types of heart failure and how they affect you
Medically reviewed by Jeffrey S. Lander, MD Key Takeaways Heart failure happens when the heart can't pump enough blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback